Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Asparaginase formulations in ALL treatment: products available and their side effect profiles

Lauren Huang • 8 Dec 2023
ASH 2023
Acute Lymphoblastic Leukemia Leukemia Asparaginase Calaspargase pegol Erwinia asparaginase PEG-asparaginase

In this video, Lauren Huang, DNP, ARNP, PNP-PC, Seattle Children’s Hospital, Seattle, WA, discusses the role of asparaginase formulations in the treatment of acute lymphoblastic leukemia (ALL) and highlights the side effect profile of these drugs. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals